Treating hepatitis C virus in HIV patients: are side effects a real obstacle?
AIDS Rev
; 9(1): 16-24, 2007.
Article
en En
| MEDLINE
| ID: mdl-17474310
ABSTRACT
Hepatitis C virus-related long-term complications are nowadays a leading cause of morbidity and mortality in HIV-infected persons. According to international guidelines, all HIV/HCV-coinfected patients should be evaluated and, if eligible, treated with pegylated interferon plus ribavirin. The management of anti-HCV treatment side effects, which may be even more serious in HIV patients, is very important to minimize treatment early discontinuations. The purpose of this review is to supply clinicians with an update, provided by the most recent and relevant literature, of underlying mechanisms, incidence, and advice about the management of pegylated interferon and ribavirin side effects in HCV/HIV-coinfected patients.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Hepatitis C
/
Hepacivirus
Tipo de estudio:
Guideline
Idioma:
En
Revista:
AIDS Rev
Asunto de la revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Año:
2007
Tipo del documento:
Article